199 related articles for article (PubMed ID: 19879974)
1. A two-stage algorithm for designing phase I cancer clinical trials for two new molecular entities.
Su Z
Contemp Clin Trials; 2010 Jan; 31(1):105-7. PubMed ID: 19879974
[TBL] [Abstract][Full Text] [Related]
2. A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.
Paoletti X; Kramar A
Stat Med; 2009 Oct; 28(24):3012-28. PubMed ID: 19672839
[TBL] [Abstract][Full Text] [Related]
3. An optimization algorithm for designing phase I cancer clinical trials.
Jiang H; Liu Y; Su Z
Contemp Clin Trials; 2008 Mar; 29(2):102-8. PubMed ID: 17681867
[TBL] [Abstract][Full Text] [Related]
4. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
Normolle D; Lawrence T
J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
[TBL] [Abstract][Full Text] [Related]
5. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
[TBL] [Abstract][Full Text] [Related]
6. Three-dose-cohort designs in cancer phase I trials.
Huang B; Chappell R
Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
[TBL] [Abstract][Full Text] [Related]
7. A hybrid Bayesian adaptive design for dose response trials.
Chang M; Chow SC
J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172
[TBL] [Abstract][Full Text] [Related]
8. A model-based approach in the estimation of the maximum tolerated dose in phase I cancer clinical trials.
He W; Liu J; Binkowitz B; Quan H
Stat Med; 2006 Jun; 25(12):2027-42. PubMed ID: 16025542
[TBL] [Abstract][Full Text] [Related]
9. [Continual reassessment method (CRM)].
Ishizuka N
Gan To Kagaku Ryoho; 2000 Aug; 27(9):1449-57. PubMed ID: 10969605
[TBL] [Abstract][Full Text] [Related]
10. The continual reassessment method for multiple toxicity grades: a Bayesian quasi-likelihood approach.
Yuan Z; Chappell R; Bailey H
Biometrics; 2007 Mar; 63(1):173-9. PubMed ID: 17447942
[TBL] [Abstract][Full Text] [Related]
11. Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control.
Tighiouart M; Rogatko A; Babb JS
Stat Med; 2005 Jul; 24(14):2183-96. PubMed ID: 15909291
[TBL] [Abstract][Full Text] [Related]
12. Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes.
Resche-Rigon M; Zohar S; Chevret S
Clin Trials; 2008; 5(6):595-606. PubMed ID: 19029208
[TBL] [Abstract][Full Text] [Related]
13. Practical modifications of the continual reassessment method for phase I cancer clinical trials.
Faries D
J Biopharm Stat; 1994 Jul; 4(2):147-64. PubMed ID: 7951271
[TBL] [Abstract][Full Text] [Related]
14. Choice of designs and doses for early phase trials.
Zhou Y
Fundam Clin Pharmacol; 2004 Jun; 18(3):373-8. PubMed ID: 15147290
[TBL] [Abstract][Full Text] [Related]
15. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
Gerke O; Siedentop H
Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity in phase I clinical trials: prior elicitation and computation using the continual reassessment method.
Legedza AT; Ibrahim JG
Stat Med; 2001 Mar; 20(6):867-82. PubMed ID: 11252009
[TBL] [Abstract][Full Text] [Related]
17. Alternative designs of phase II trials considering response and toxicity.
Jin H
Contemp Clin Trials; 2007 Jul; 28(4):525-31. PubMed ID: 17428744
[TBL] [Abstract][Full Text] [Related]
18. Dose-escalation designs in oncology: ADEPT and the CRM.
Shu J; O'Quigley J
Stat Med; 2008 Nov; 27(26):5345-53; discussion 5354-5. PubMed ID: 18752259
[TBL] [Abstract][Full Text] [Related]
19. Adaptive Bayesian design for phase I dose-finding trials using a joint model of response and toxicity.
Wang M; Day R
J Biopharm Stat; 2010 Jan; 20(1):125-44. PubMed ID: 20077253
[TBL] [Abstract][Full Text] [Related]
20. A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials.
Pan H; Yuan Y
Stat Med; 2017 Jan; 36(2):266-279. PubMed ID: 26991076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]